SEC Comment Letter 0000000000-23-000092 to LAVA Therapeutics NV (LVTX) (CIK 0001840748)

LAVA Therapeutics NV (LVTX) (CIK 0001840748)
Date: Jan. 4, 2023 · CIK: 0001840748 · Accession: 0000000000-23-000092

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-40241

Date

January 4, 2023

Author

Not clearly detected

Form

UPLOAD

Company

LAVA Therapeutics NV (LVTX) (CIK 0001840748)

Letter

United States securities and exchange commission logo January 4, 2023 Fred Powell Chief Financial Officer LAVA Therapeutics N.V. 520 Walnut St, Suite 1150 Philadelphia, PA 19106 Re:LAVA Therapeutics N.V. Form 20-F for the Fiscal Year Ended December 31, 2021 Filed March 24, 2022 File No. 001-40241 Dear Fred Powell: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
January 4, 2023
Fred Powell
Chief Financial Officer
LAVA Therapeutics N.V.
520 Walnut St, Suite 1150
Philadelphia, PA 19106
Re:LAVA Therapeutics N.V.
Form 20-F for the Fiscal Year Ended December 31, 2021
Filed March 24, 2022
File No. 001-40241
Dear Fred Powell:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io